Murat Kiyici

Murat Kiyici

Auto-generated profile, based on publicly available information

Murat Kiyici

Department of Gastroenterology, Bursa Uludağ University School of Medicine, Bursa, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
MAMesut Akarsu
Mesut Akarsu
SÖSoner Önem
Soner Önem
ITIlker Turan
Ilker Turan
GAGupse Adali
Gupse Adali
MAMeral Akdogan
Meral Akdogan
ZKZeki Karasu
Zeki Karasu
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation.

1 January 2024 in Hepatology Forum
Verified
Journal Article
Open access
MAMesut Akarsu
Mesut Akarsu
SDSüleyman DOLU
Süleyman DOLU
MHMURAT HARPUTLUOGLU
MURAT HARPUTLUOGLU
SYSezai Yilmaz
Sezai Yilmaz
MAMurat Akyildiz
Murat Akyildiz
RIRamazan Idilman
Ramazan Idilman
Background and Aim: This study aimed to identify the indications for liv-er transplantation (LT) based on underlying etiology and to characterize the patients who underwent LT. Materials and Methods: We conducted a multicenter crosssectional ob-servational study across 11 tertiary centers in Turkiye from 2010 to 2020. The study included 5,080 adult patients. Results: The mean age of patients was 50.3±15.2 years, with a predominance of female patients (70%). Chronic viral hepatitis (46%) was the leading etiological factor, with Hepatitis B virus infection at 35%, followed by cryptogenic cirrhosis (24%), Hepatitis C virus infection (8%), and al-cohol-related liver disease (ALD) (6%). Post-2015, there was a significant increase in both the number of liver transplants and the proportion of living donor liver transplants (p

15 March 2024 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
MTMustafa Tahtaci
Mustafa Tahtaci
EYEmre Yıldırım
Emre Yıldırım
EÜEnver Üçbilek
Enver Üçbilek
IŞİlKer Şen
İlKer Şen
GBGülden Bilican
Gülden Bilican
TKTarkan Karakan
Tarkan Karakan
Background/Aims: Gastroenterologists have an important role in the treatment and management of comorbidities related to obesity. Assessment of gastroenterologists perception and attitude toward obesity was aimed in this study. Materials and Methods: Survey questions were determined for the study. An online questionnaire was prepared afterward. Participants were invited via e-mail by providing them with information about the study. It was ensured that those who accepted the study could access the questionnaire form with the relevant link. Participants who answered all questions were included in the study. Results: Totally 117 gastroenterologists were included in the study. The proportion of gastroenterologists who thought that obesity complicates the management of gastroenterological diseases and those who thought obesity as a factor that negatively affects the prognosis of gastroenterological diseases was determined as 88.9% and 95.7%, respectively. Among the obese patients, the proportion of those who applied diet therapy, exercise, pharmacotherapy, and endoscopic methods was 94%, 91.5%, 35%, and 37.6%, respectively. The rates of intragastric balloon therapy and intragastric botulinum toxin A injection were 30% and 21.4%, respectively. The proportion of those who agreed that obese patients lost a significant amount of weight with the treatment methods applied was 47.2%. The proportion of participants who agreed that long-term maintenance of weight loss was impossible for most obese patients was 59.8%. Conclusion: To our knowledge, this is the first study that evaluates the perception and attitude of gastroenterologists toward obesity. Our study results show that gastroenterologists think that obesity is a chronic disease and that gastroenterologists should be involved in management of obesity. Cite this article as: Tahtacı M, Yıldırım E, Ç bilek E, et al. Perception and attitude of Turkish gastroenterologists toward obesity: A nationwide survey conducted by the Obesity Study Group of the Turkish Gastroenterology Association. Turk J Gastroenterol. 2024;35(3):161-167.

13 April 2026 in Liver Transplantation
Verified
Journal Article
Closed access
KMKenan Moral
Kenan Moral
MHMURAT HARPUTLUOGLU
MURAT HARPUTLUOGLU
GÖGülşah Fidan Özkumur
Gülşah Fidan Özkumur
DGDOĞAN CAN GAVCAR
DOĞAN CAN GAVCAR
EEEfe Erbay
Efe Erbay
GKGökhan Kabacam
Gökhan Kabacam
The Model for End-stage Liver Disease Sodium (MELD-Na) score predicts mortality in liver transplant candidates. MELD 3.0 has been proposed as an improved model for estimating mortality risk. This study evaluated MELD 3.0’s predictive accuracy for short-term mortality among Turkish liver transplant candidates and compared its performance with MELD and MELD-Na scores. Patients listed both for deceased donor transplants and living donor transplants were analyzed in the study. The discriminative abilities of MELD, MELD-Na, and MELD 3.0 scores were assessed using the area under the receiver operating characteristic curve (AUROC). Comparisons between AUROC values used the DeLong test. The most predictive cutoff for MELD 3.0 was determined using the Youden index. Transplant-free survival was analyzed using the Kaplan–Meier method, with survival curves compared using the log-rank test. A total of 1689 patients were included in this nationwide, multicenter study. Hepatitis B was the leading cause of cirrhosis (29%, n=491), followed by metabolic dysfunction–associated steatohepatitis (20%, n=335). For 3-month mortality, MELD 3.0 had the highest AUROC (0.753), followed by MELD-Na (0.747) and MELD (0.725). The most predictive cutoff values were 18 for MELD and 21 for MELD-Na and MELD 3.0. Both MELD-Na and MELD 3.0 outperformed MELD ( p <0.001), but showed no significant difference between them ( p =0.17). MELD 3.0 and MELD-Na demonstrated superior performance to MELD in predicting 3-month mortality among Turkish liver transplant candidates, though their predictive accuracy was comparable. Further refinements are needed to enhance MELD 3.0’s clinical utility.

29 January 2022 in Turkish Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
BYBurcu Yagiz
Burcu Yagiz
BCBelkis Nihan Coşkun
Belkis Nihan Coşkun
TOTuğba OCAK
Tuğba OCAK
AGAltuğ Güner
Altuğ Güner
AMAslı MACUNLUOGLU
Aslı MACUNLUOGLU
HDHüseyin Ediz Dalkiliç
Hüseyin Ediz Dalkiliç
Introduction: Chronic inflammatory diseases (CIDs) are lifelong complex disorders that affect quality of life, and this study aimed to summarize 5 years of experience with a multidisciplinary approach for these complex diseases as a result of medical council meetings. Methods: Hospital-based, medical records review study was conducted. A total of 45 monthly medical council meetings were held between 2014-2019 with the participation of the rheumatology, dermatology and gastroenterology departments of the same university. Patients with complex conditions that were seen in each department's own polyclinic composed the council. This study only included 308 patients referred by the rheumatology group. Results: Females made up 66.5 % of the 308 patients. The median age was 45 (19-77). PsA (psoriatic arthritis) and other SPA (spondyloarthritis) patients composed 49.3% of the total. A total of 68.18% of the patients were presented only to consult with the dermatology department. The most common reason for presenting patients was to discuss options for treatment (41.5%). The diagnosis of psoriasis was confirmed in 48 of 67 (71.6%) patients who presented with a pre-diagnosis. The diagnosis was changed in 34.74% of the patients, whereas the diagnosis became completely different in 11.36% of the patients. Conclusions: Many patients with challenging diagnosis and treatment processes are encountered in daily practice. The combination of different disciplines makes it possible to provide more rapid and effective solutions. In this study, we aimed to emphasize the increasing importance of such multidisciplinary approaches

20 February 2026 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
NDNilay Danis
Nilay Danis
HDHüseyin DÖNGELLİ
Hüseyin DÖNGELLİ
TUTARKAN UNEK
TARKAN UNEK
ABAylin Bacakoğlu
Aylin Bacakoğlu
ITİlKer Turan
İlKer Turan
MAMesut Akarsu
Mesut Akarsu
Background/Aims: De novo malignancies are an important long-term complication following liver transplantation (LT), driven bychronic immunosuppression and extended post-transplant survival. Understanding patterns by tumor type, timing, and patient characteristics is essential for optimized surveillance. This study aimed to evaluate the clinical characteristics and temporal trends of de novoneoplasms in LT recipients.Materials and Methods: A total of 6943 adult LT recipients from 16 Turkish centers were evaluated between 1999 and 2023). Two hundred eight patients with 220 histologically confirmed de novo malignancies (excluding hepatocellular carcinoma) were included. Patientswho died within 30 days or developed cancer within 90 days post-LT were excluded. Incidence and mortality rates were assessed acrosspost-transplant intervals.Results: Non-skin solid (53.2%), dermatologic (28.6%), and hematologic (18.2%) cancers were predominant. Most malignancies (76.8%)occurred within 10 years post-LT. Early-onset (<10 years) malignancies were more common in living donor recipients (62.7%, P = .001)and associated with higher mortality (39.6% vs. 11.8%, P < .001). Recipients ≤60 years exhibited a higher incidence of hematologiccancers (23.9% vs. 12.6%, P = .03) and increased mortality (39.4% vs. 27.0%, P = .05). In subgroup analysis, tacrolimus use was stronglyassociated with cutaneous squamous cell carcinoma (P = .004). Peak incidence occurred 2-10 years post-LT (≈13-14 per 1000 recipients), with non-skin solid tumors being the most frequent.Conclusion: De novo malignancies remain a significant long-term risk after LT, with outcomes influenced by tumor type, age, immunosuppression, and timing of onset. Risk-adapted surveillance and tailored oncologic management, particularly dermatologic screeningin tacrolimus-treated patients and enhanced surveillance during the 2-10 year post-transplant period are recommended to improvelong-term survival.Cite this article as: Danış N, Döngelli H, Ünek T, et al. De novo malignancies after liver transplantation: A multicenter cohort studyof incidence, timing, and outcomes. Turk J Gastroenterol. Published online February 20, 2026. doi:10.5152/tjg.2026.25748.